The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Covalent Modifiers: An Orthogonal Approach to Drug Design
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTCovalent Modifiers: An Orthogonal Approach to Drug DesignMichele H. Potashman* and Mark E. Duggan*§View Author Information Department of Medicinal Chemistry, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139* To whom correspondence should be addressed. For M.H.P.: phone, (617) 444-5010; fax, (617) 577-9288; e-mail, [email protected]. For M.E.D.: phone, (617) 583-1983; e-mail, [email protected]§Current address: Link Medicine Inc., 161 First Street, Cambridge, MA 02142.Cite this: J. Med. Chem. 2009, 52, 5, 1231–1246Publication Date (Web):February 9, 2009Publication History Received11 July 2008Published online9 February 2009Published inissue 12 March 2009https://pubs.acs.org/doi/10.1021/jm8008597https://doi.org/10.1021/jm8008597review-articleACS PublicationsCopyright © 2009 American Chemical SocietyRequest reuse permissionsArticle Views16521Altmetric-Citations288LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Adducts,Inhibition,Inhibitors,Monomers,Peptides and proteins Get e-Alerts
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
Powers, J. C., Asgian, J. L., Ekici, Ö. D., & James, K. E. (2002) · Chemical Reviews · doi:10.1021/cr010182v · Cited by 1,090
Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
Identification and Biological Activity of the Active Metabolite of Clopidogrel
Savi, P., Pereillo, J. M., Uzabiaga, M. F., Combalbert, J., Picard, C., Maffrand, J. P., Pascal, M., & Herbert, J. M. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614133 · Cited by 754
Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., & Baillie, T. A. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034170b · Cited by 706
Modification of the NADH of the Isoniazid Target (InhA) from Mycobacterium tuberculosis
Rozwarski, D. A., Grant, G. A., Barton, D. H. R., Jacobs, W. R., & Sacchettini, J. C. (1998) · Science · doi:10.1126/science.279.5347.98 · Cited by 682
Multimodular Penicillin-Binding Proteins: An Enigmatic Family of Orthologs and Paralogs
Goffin, C., & Ghuysen, J.-M. (1998) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.62.4.1079-1093.1998 · Cited by 636
An Antifungal Agent Inhibits an Aminoacyl-tRNA Synthetase by Trapping tRNA in the Editing Site
Rock, F. L., Mao, W., Yaremchuk, A., Tukalo, M., Crépin, T., Zhou, H., Zhang, Y.-K., Hernandez, V., Akama, T., Baker, S. J., et al. (2007) · Science · doi:10.1126/science.1142189 · Cited by 631
Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate
Santi, D. V., McHenry, C. S., & Sommer, H. (1974) · Biochemistry · doi:10.1021/bi00700a012 · Cited by 619
A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups
Kalgutkar, A., Gardner, I., Obach, R., Shaffer, C., Callegari, E., Henne, K., Mutlib, A., Dalvie, D., Lee, J., Nakai, Y., et al. (2005) · Current Drug Metabolism · doi:10.2174/1389200054021799 · Cited by 616
Cited by
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 652
Jackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 587
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Rankovic, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501535r · Cited by 548
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L., McFarland, J. M., Miller, R. M., Frödin, M., & Taunton, J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.925 · Cited by 493
A Perspective on the Kinetics of Covalent and Irreversible Inhibition
Strelow, J. M. (2017) · SLAS Discovery · doi:10.1177/1087057116671509 · Cited by 392
Lead‐Oriented Synthesis: A New Opportunity for Synthetic Chemistry
Nadin, A., Hattotuwagama, C., & Churcher, I. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201105840 · Cited by 390
Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors
Lanning, B. R., Whitby, L. R., Dix, M. M., Douhan, J., Gilbert, A. M., Hett, E. C., Johnson, T. O., Joslyn, C., Kath, J. C., Niessen, S., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1582 · Cited by 359
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
Barf, T., & Kaptein, A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3003203 · Cited by 331
Flanagan, M. E., Abramite, J. A., Anderson, D. P., Aulabaugh, A., Dahal, U. P., Gilbert, A. M., Li, C., Montgomery, J., Oppenheimer, S. R., Ryder, T., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501412a · Cited by 320
Advances in covalent kinase inhibitors
Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R., & Gunning, P. T. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00720b · Cited by 317
The pharmacological landscape and therapeutic potential of serine hydrolases
Bachovchin, D. A., & Cravatt, B. F. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3620 · Cited by 308
Rizzo, M. R., Barbieri, M., Marfella, R., & Paolisso, G. (2012) · Diabetes Care · doi:10.2337/dc12-0199 · Cited by 303
Smith, M. C., & Gestwicki, J. E. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.10 · Cited by 286
Chen, W., Dong, J., Plate, L., Mortenson, D. E., Brighty, G. J., Li, S., Liu, Y., Galmozzi, A., Lee, P. S., Hulce, J. J., et al. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b02960 · Cited by 286
Covalent docking of large libraries for the discovery of chemical probes
London, N., Miller, R. M., Krishnan, S., Uchida, K., Irwin, J. J., Eidam, O., Gibold, L., Cimermančič, P., Bonnet, R., Shoichet, B. K., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1666 · Cited by 274
Electrophilic natural products and their biological targets
Gersch, M., Kreuzer, J., & Sieber, S. A. (2012) · Natural Product Reports · doi:10.1039/c2np20012k · Cited by 282
Krishnan, S., Miller, R. M., Tian, B., Mullins, R. D., Jacobson, M. P., & Taunton, J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505194w · Cited by 260
Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls
Kumalo, H., Bhakat, S., & Soliman, M. (2015) · Molecules · doi:10.3390/molecules20021984 · Cited by 158
Covalent inhibitors: an opportunity for rational target selectivity
Lagoutte, R., Patouret, R., & Winssinger, N. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.05.008 · Cited by 138
Ouyang, X., Zhou, S., Su, C. T. T., Ge, Z., Li, R., & Kwoh, C. K. (2013) · Journal of Computational Chemistry · doi:10.1002/jcc.23136 · Cited by 134
The Design of Covalent Allosteric Drugs
Nussinov, R., & Tsai, C.-J. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124401 · Cited by 112
New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design
Ray, S., & Murkin, A. S. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00293 · Cited by 108
Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
Goedken, E. R., Argiriadi, M. A., Banach, D. L., Fiamengo, B. A., Foley, S. E., Frank, K. E., George, J. S., Harris, C. M., Hobson, A. D., Ihle, D. C., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.595181 · Cited by 101
Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine
Hagel, M., Niu, D., St Martin, T., Sheets, M. P., Qiao, L., Bernard, H., Karp, R. M., Zhu, Z., Labenski, M. T., Chaturvedi, P., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.492 · Cited by 95
Modeling covalent-modifier drugs.
Awoonor-Williams, E., Walsh, A. G., & Rowley, C. N. (2017) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2017.05.009 · Cited by 90
Zambaldo, C., Daguer, J.-P., Saarbach, J., Barluenga, S., & Winssinger, N. (2016) · MedChemComm · doi:10.1039/c6md00242k · Cited by 75
Nguyen, V. S., Loh, X. Y., Wijaya, H., Wang, J., Lin, Q., Lam, Y., Wong, W.-S. F., & Mok, Y. K. (2015) · Journal of Natural Products · doi:10.1021/np5007179 · Cited by 66
Basu, D., Richters, A., & Rauh, D. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.038 · Cited by 50
Metadata
- Authors
- Potashman, M. H., & Duggan, M. E.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2009-02-09
- Volume
- 52
- Issue
- 5
- Pages
- 1231-1246
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2078585784
- Cited by
- 346
- References
- 60
- FWCI
- 12.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.